Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Detection of Molecular Residual Disease in Early-Stage Non-Small Cell Lung Cancer

NCT07854769 is registered in ClinicalTrials.gov with Fox Chase Cancer Center as lead sponsor.

NCT NCT07854769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07854769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Detection of Molecular Residual Disease in Early-Stage Non-Small Cell Lung Cancer
Lead sponsor
Fox Chase Cancer Center
Phase
Observational
Overall status
Not yet recruiting
Start date
October 6, 2026
Completion date
October 5, 2031
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer